Are statin medications safe in patients with ALS?

Amyotrophic Lateral Sclerosis

Volumn 9, Issue 4, 2008, Pages 223-228

  Zinman, Lorne ^a   Sadeghi, Reza ^a   Gawel, Marek ^a   Patton, Dan ^a   Kiss, Alex ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

ALSFRS R; Amyotrophic lateral sclerosis; HMG CoA reductase inhibitors; Muscle cramps; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; RILUZOLE; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIET THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTICHOLESTEREMIC AGENTS; CREATINE KINASE; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCLE CRAMP; PROSPECTIVE STUDIES; VITAL CAPACITY;

EID: 48249090462     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960802031092     Document Type: Article

References (26)

1. Krivickas, LS, Yang, J., Kim, S. and Frontera, WR. (2002) Skeletal muscle fibre function and rate of disease progression in amyotrophic lateral sclerosis. 26, pp. 636-643.
2. Achari, AN and Anderson, MS. (1974) Myopathic changes in amyotrophic lateral sclerosis-pathologic analysis of muscle biopsy changes in 111 cases. 24, pp. 477-481.
3. Sussmuth, SD, Tumani, H., Ecker, D. and Ludolph, AC. (2003) Amyotrophic lateral sclerosis: Disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. 353, pp. 57-60.
4. Ilzecka, J. and Stelmasiak, Z. (2003) Creatine kinase activity in amyotrophic lateral sclerosis patients. 24, pp. 286-287.
5. Felice, KJ and North, WA. (1998) Creatine kinase values in amyotrophic lateral sclerosis. 160, p. S30.
6. Schreiber, DH and Anderson, TR. (2006) Statin-induced rhabdomyolysis. 31, pp. 177-180.
7. Watson, KE and Fonarow, GC. (2005) The past, present, and future of statin therapy. 6, pp. 129-139.
8. Tousoulis, D., Charakida, M., Stefanadi, E., Siasos, G., Latsios, G. and Stefanadis, C. (2007) Statins in heart failure. Beyond the lipid lowering effect. 115, pp. 144-150.
9. Thompson, PD, Clarkson, P. and Karas, RH. (2003) Statin-associated myopathy. 289, pp. 1681-1690.
10. Vladutiu, GD, Simmons, Z., Isackson, PJ, Tarnopolsky, M., Peltier, WL Barboi, AC et al. (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies. 34, pp. 153-162.
11. Phan, T., McLeod, JG, Pollard, JD, Peiris, O., Rohan, A. and Halpern, JP. (1995) Peripheral neuropathy associated with simvastatin. 58, pp. 625-628.
12. Gaist, D., Garcia Rodriguez, LA, Huerta, C., Hallas, J. and Sindrup, SH. (2001) Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?. 56, pp. 931-933.
13. Folkers, K., Langsjoen, P., Willis, R., Richardson, P., Xia, LJ Ye, CQ et al. (1990) Lovastatin decreases coenzyme Q levels in humans. 87, pp. 8931-8934.
14. Cutler, RG, Pedersen, WA, Camandola, S., Rothstein, JD and Mattson, MP. (2002) Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. 52, pp. 448-457.
15. Bosel, J., Gandor, F., Harms, C., Synowitz, M., Harms, U. Djoufack, PC et al. (2005) Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurons. 92, pp. 1386-1398.
16. Arnaud, C., Braunersreuther, V. and Mach, F. (2005) Toward immunomodulatory and anti-inflammatory properties of statins. 15, pp. 202-206.
17. Wolozin, B., Wang, SW, Li, NC, Lee, A., Lee, TA and Kazis, LE. (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. 19, pp. 5-20.
18. Gordon, P., Miller, R. and Moore, D. (2004) ALSFRS-R. 5, pp. 90-93.
19. Cedarbaum, JM, Stambler, N., Malta, E., Fuller, C., Hilt, D. Thurmond, B. et al. (1999) The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. 169, pp. 13-21.
20. Brooks, BR, Miller, RG, Swash, M. and Munsat, TL (2000) World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1, pp. 293-299.
21. Cohen, J. (1988) Lawrence Erlbaum Associates Inc, New Jersey
22. Miller, R., Bradley, W., Cudkowicz, M., Hubble, J., Meininger, V. Mitsumoto, H. et al. (2007) Phase II/III randomized trial of TCH346 in patients with ALS. 69, pp. 776-784.
23. Gordon, PH, Moore, DH, Miller, RG, Florence, JM, Verheijde, JL Doorish, C. et al. (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomized trial. 6, pp. 1045-1053.
24. Desport, JC, Torny, F., Lacoste, M., Preux, PM and Couratier, P. (2005) Hypermetabolism in ALS: Correlations with clinical and paraclinical parameters. 2, pp. 202-207.
25. Dupuis, L., Oudart, H., Rene, F., Gonzalez de Aguilar, JL and Loeffler, JP. (2004) Evidencefor defective energy homeostasis in amyotrophic lateral sclerosis: Benefitof a high-energy diet in a transgenic mouse model. 101, pp. 11159-11164.
26. Qureshi, MM, Hayden, D., Urbinelli, L., Ferrante, K., Newhall, K. Myers, D. et al. (2006) Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). 7, pp. 173-182.